發作性睡病藥物市場規模、佔有率、成長分析，按疾病類型、治療藥物類型、地區分類 - 產業預測，2024-2031 年

Narcolepsy Drugs Market Size, Share, Growth Analysis, By Disease Type (Daytime Extreme Sleepiness, Cataplexia), By Therapeutics Type (Central Nervous System Stimulants, Tricyclic Antidepressants), By Region - Industry Forecast 2024-2031

出版日期: 2024年10月03日 | 出版商:

SkyQuest | 英文 219 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

2022年全球發作性睡病藥物市場規模估值約34億美元，高於2023年的37億美元，預測期內（2024-2031年）複合年成長率為9.5%，預計將達10億美元。

由於幾個關鍵因素，包括人口老化，更容易患需要醫療照護的慢性和急性疾病，預計發作性睡病藥物市場將顯著成長。生活方式的改變和壓力水平的上升加劇了發作性睡病的增加，預計未來幾年將進一步推動市場擴張。加強研究舉措、增加醫療支出和改善醫療基礎設施支持了這一成長潛力。此外，我們的研究結果表明，調整晝夜節律、增加睡眠時間和實施遠程辦公等因素可以有效控制與中樞性嗜睡症相關的症狀，從而鼓勵人們廣泛接受發作性睡病治療。然而，治療和診斷相關的高成本以及對可用治療方法整體缺乏認知等挑戰也可能阻礙市場的進步。不利的報銷條件也可能是一個主要障礙，影響專注於針對性研究和開發的製藥公司的商機。儘管面臨這些挑戰，美國市場情勢預計在下一個預測期內將保持穩定的複合年成長率。這反映了在不斷發展的醫療保健環境中對治療的持續需求，該環境越來越優先考慮與睡眠相關的疾病。

市場概況
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲國家地區
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 其他亞太地區
拉丁美洲
- 巴西
- 其他拉丁美洲地區
中東和非洲 (MEA)
- 海灣合作理事會國家
- 南非
- 其他中東/非洲地區

競爭格局

前5名企業對比
主要企業市場定位（2023年）
主要市場參與者所採取的策略
近期市集活動
主要企業市場佔有率（2023年）

主要企業簡介

Jazz Pharmaceuticals plc
Teva Pharmaceutical Industries Ltd.
Bioprojet Pharma SARL
Novartis International AG
Takeda Pharmaceutical Company
Avadel Pharmaceuticals
Mylan NV（now part of Viatris）
Aurobindo Pharma
Glenmark Pharmaceuticals
Lupin Pharmaceuticals
Otsuka Pharmaceutical
Biogen
Theravance Biopharma
Ligand Pharmaceuticals
Flamel Technologies（now Avadel Pharmaceuticals）
Biocodex
Sun Pharmaceutical Industries
Cipla Limited
Dr. Reddy's Laboratories
Pfizer Inc.

簡介目錄

Product Code: SQMIG35I2087

Global Narcolepsy Drugs Market size was valued at around USD 3.4 billion in 2022 and is expected to rise from USD 3.7 billion in 2023 to reach a value of USD 7 billion by 2031, at a CAGR of 9.5% over the forecast period (2024-2031).

The narcolepsy therapeutics market is poised for substantial growth driven by several key factors, primarily the aging population's increased susceptibility to chronic and acute ailments necessitating medical care. The rise in narcoleptic disorders, exacerbated by evolving lifestyles and heightened stress levels, is expected to further fuel market expansion in the coming years. Enhanced research initiatives, increased healthcare spending, and improved medical infrastructure underscore this growth potential. Additionally, factors such as circadian adjustment, increased sleep, and telework practices suggest that symptoms associated with central hypersomnia can be effectively managed, encouraging a broader acceptance of narcolepsy treatments. However, challenges exist, notably the high costs associated with treatments and diagnostics, coupled with an overarching lack of awareness regarding available therapies, which are likely to hinder market progress. The unfavorable reimbursement landscape also poses significant obstacles, potentially impacting revenue opportunities for pharmaceutical companies focused on targeted research and development. Despite these challenges, the US narcolepsy drugs market is expected to experience a steady compound annual growth rate (CAGR) over the next forecast period, reflecting a resilient demand for treatments amid an evolving healthcare landscape that increasingly prioritizes sleep-related disorders.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Narcolepsy Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Narcolepsy Drugs Market Segmental Analysis

Global Narcolepsy Drugs Market is segmented by Disease Type, Therapeutics Type, and region. Based on Disease Type, the market is segmented into Daytime Extreme Sleepiness, Cataplexia, and Other Disease Type. Based on Therapeutics Type, the market is segmented into Central Nervous System Stimulants, Tricyclic Antidepressants, Sodium Oxybate, Selective Serotonin Reuptake Inhibitor, and Other Therapeutic Type. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & and Africa.

Driver of the Global Narcolepsy Drugs Market

Growing awareness surrounding narcolepsy treatment plays a crucial role in driving the Global Narcolepsy Drugs market from 2023 to 2030. As more patients and healthcare providers recognize the impact of the condition on quality of life, the demand for effective treatments is surging. Notably, the preference for modafinil, which is known for its favorable safety profile compared to traditional stimulants, is further contributing to this trend. This increased focus on appropriate therapeutic options not only enhances patient outcomes but also fosters market growth, as effective therapies become more widely adopted, driving sales and innovation within the narcolepsy drug sector.

Restraints in the Global Narcolepsy Drugs Market

A significant market restraint for the global narcolepsy drugs market is the frequent misdiagnosis of narcolepsy symptoms, which are often confused with various mental and neurological disorders. This lack of awareness leads to inappropriate prescriptions of antiepileptics and psychiatric medications, particularly in children and adolescents, potentially causing adverse health effects. The resulting hesitation from healthcare providers to accurately diagnose and treat narcolepsy can hinder market growth, as patients may not receive the necessary therapy for their condition. Additionally, this confusion can create mistrust among patients towards seeking effective treatments, further limiting market opportunities for narcolepsy drug manufacturers.

Market Trends of the Global Narcolepsy Drugs Market

The global narcolepsy drugs market is poised for significant growth, fueled by the rising prevalence of narcolepsy and associated sleep disorders across diverse demographics. Increasing incidences of obesity-related narcolepsy variants further bolster market expansion, highlighting the pressing need for effective therapeutic solutions. Government initiatives aimed at enhancing awareness and understanding of narcolepsy are anticipated to drive demand for treatment options. Moreover, hospitals are emerging as the primary end-use sector, capturing the largest share of the market as more patients seek specialized care. Overall, this confluence of factors positions the narcolepsy drugs market for robust growth in the coming years.

Introduction

Objectives of the Study
Definitions
Market Scope

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Market Overview Outlook
Supply Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers

Key Market Insights

Key Success Factor
Degree of Competition
Top Investment Pockets
Ecosystem of the Market
Regulatory Analysis
Case Study Analysis
Clinical Trials

Narcolepsy Drugs Market, By Disease Type

Market Overview
Daytime Extreme Sleepiness
Cataplexia
Other Disease Type

Narcolepsy Drugs Market, By Therapeutics Type

Market Overview
Central Nervous System Stimulants
Tricyclic Antidepressants
Sodium Oxybate
Selective Serotonin Reuptake Inhibitor
Other Therapeutic Type

Narcolepsy Drugs Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2023
Strategies Adopted by Key Market Players
Recent Activities in the Market
Key Companies Market Share (%), 2023

Key Company Profiles

Jazz Pharmaceuticals plc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Teva Pharmaceutical Industries Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bioprojet Pharma SARL
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis International AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Takeda Pharmaceutical Company
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Avadel Pharmaceuticals
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Mylan N.V. (now part of Viatris)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Aurobindo Pharma
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Glenmark Pharmaceuticals
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Lupin Pharmaceuticals
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Otsuka Pharmaceutical
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Biogen
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Theravance Biopharma
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Ligand Pharmaceuticals
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Flamel Technologies (now Avadel Pharmaceuticals)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Biocodex
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sun Pharmaceutical Industries
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Cipla Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Dr. Reddy's Laboratories
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments